Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease
Piero Ruscitti, Paola Cipriani, Francesco Ciccia, et al.
Clinical & Experimental Immunology (2016) Vol. 186, Iss. 1, pp. 30-38
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

A comprehensive review on adult onset Still's disease
Roberto Giacomelli, Piero Ruscitti, Yehuda Shoenfeld
Journal of Autoimmunity (2018) Vol. 93, pp. 24-36
Closed Access | Times Cited: 345
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Carlo Perricone, Elena Bartoloni, Roberto Bursi, et al.
Immunologic Research (2020) Vol. 68, Iss. 4, pp. 213-224
Open Access | Times Cited: 203
Recent advances and evolving concepts in Still’s disease
Piero Ruscitti, Luca Cantarini, Peter A. Nigrović, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 116-132
Closed Access | Times Cited: 30
Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers
Piero Ruscitti, Paola Cipriani, Francesco Masedu, et al.
BMC Medicine (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 153
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm
Piero Ruscitti, Onorina Berardicurti, Paola Di Benedetto, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 95
Iron homeostasis and disorders revisited in the sepsis
Qinjie Liu, Jie Wu, Xufei Zhang, et al.
Free Radical Biology and Medicine (2021) Vol. 165, pp. 1-13
Closed Access | Times Cited: 75
COVID-19 during Gestation: Maternal Implications of Evoked Oxidative Stress and Iron Metabolism Impairment
Jorge Moreno‐Fernández, Julio J. Ochoa, C. de Paco Matallana, et al.
Antioxidants (2022) Vol. 11, Iss. 2, pp. 184-184
Open Access | Times Cited: 47
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective
Tram Nguyen, Yoon Tae Kim, Geunyeol Jeong, et al.
Experimental & Molecular Medicine (2024) Vol. 56, Iss. 3, pp. 559-569
Open Access | Times Cited: 9
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers
Piero Ruscitti, Paola Cipriani, Francesco Ciccia, et al.
Autoimmunity Reviews (2016) Vol. 16, Iss. 1, pp. 16-21
Closed Access | Times Cited: 78
Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort
Piero Ruscitti, Daniela Iacono, Francesco Ciccia, et al.
The Journal of Rheumatology (2018) Vol. 45, Iss. 6, pp. 864-872
Open Access | Times Cited: 78
Adult-onset Still's disease with atypical cutaneous manifestations
Javier Narváez, María Pascual-Pastor, Mercè López de Recalde, et al.
Medicine (2017) Vol. 96, Iss. 11, pp. e6318-e6318
Open Access | Times Cited: 66
Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients
Piero Ruscitti, Carmela Rago, Luciana Breda, et al.
Clinical Rheumatology (2017) Vol. 36, Iss. 12, pp. 2839-2845
Closed Access | Times Cited: 66
Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review
Meng‐Yan Wang, Jinchao Jia, Chengde Yang, et al.
Chinese Medical Journal (2019) Vol. 132, Iss. 23, pp. 2856-2864
Open Access | Times Cited: 62
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations
Piero Ruscitti, Paola Di Benedetto, Onorina Berardicurti, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 52
Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies
Piero Ruscitti, Francesco Ursini, Paola Cipriani, et al.
Expert Review of Clinical Immunology (2017) Vol. 13, Iss. 11, pp. 1089-1097
Closed Access | Times Cited: 49
Adult-onset Still’s disease: A disease at the crossroad of innate immunity and autoimmunity
S. Rao, Lemuel Shui‐Lun Tsang, Ming Zhao, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 25
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome
Piero Ruscitti, Paola Cipriani, Paola Di Benedetto, et al.
Clinical & Experimental Immunology (2017) Vol. 191, Iss. 2, pp. 220-228
Open Access | Times Cited: 44
Pathogenesis of adult onset still’s disease: current understanding and new insights
Piero Ruscitti, Roberto Giacomelli
Expert Review of Clinical Immunology (2018) Vol. 14, Iss. 11, pp. 965-976
Closed Access | Times Cited: 44
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?
Piero Ruscitti, Paola Cipriani, Paola Di Benedetto, et al.
Expert Review of Clinical Immunology (2017) Vol. 13, Iss. 11, pp. 1041-1047
Closed Access | Times Cited: 41
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study
Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, et al.
Medicine (2019) Vol. 98, Iss. 15, pp. e15123-e15123
Open Access | Times Cited: 39
Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
Antonio Vitale, Giulio Cavalli, Serena Colafrancesco, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 36
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still’s disease
Piero Ruscitti, Francesco Ursini, Onorina Berardicurti, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 1, pp. 321-329
Closed Access | Times Cited: 21
Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications
Piero Ruscitti, Ilenia Di Cola, Claudia Di Muzio, et al.
Autoimmunity Reviews (2022) Vol. 21, Iss. 7, pp. 103114-103114
Closed Access | Times Cited: 20
Activation mechanisms of monocytes/macrophages in adult-onset Still disease
Hiroto Tsuboi, Seiji Segawa, Mizuki Yagishita, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Hyperferritinaemia: An Iron Sword of Autoimmunity
Joanna Giemza-Stokłosa, Md Asiful Islam, Przemysław Kotyla
Current Pharmaceutical Design (2019) Vol. 25, Iss. 27, pp. 2909-2918
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top